CLOs on the Move

Trumpet Behavioral Health

www.tbh.com

 
TBH is a leading provider of behavioral health services. We specialize in the treatment of children and adults with Autism Spectrum Disorders and developmental disabilities, using the principles of Applied Behavior Analysis (ABA). TBH is proud to employ a talented staff dedicated to its mission and values, constructing a team of experienced, caring and enthusiastic individuals to coordinate the best behavior program possible for children, adults and families. Further, TBH`s collaborative efforts mean that parents, schools, agencies, Supervisors and Skills Trainers all play important roles in behavior programs, forming a large team dedicated to the needs of each client. TBH ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.tbh.com
  • 390 Union Blvd. Suite 300
    Lakewood, CO USA 80228
  • Phone: 303.989.8169

Executives

Name Title Contact Details

Similar Companies

Train for Compliance

Train for Compliance is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infusion Systems

Infusion Systems is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Institute for Healthcare Communication

Institute for Healthcare Communication is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Twin County Airport

Twin County Airport is a Hillsville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.